Aktie A116WM CANNABICS PHARMACEUTICALS INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Cannabics Pharmaceuticals Inc. Other OTC

Aktien

A116WM

US13764M1009

CNBX

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024
CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023
BigTime Penny Stocks: Unusual "Chatter" Watchlist (GEGI, AAPJ, CNBX, GTVH)
BigTime Penny Stocks: Potential Breakout Stocks - Watchlist (GNPX, CLNV, CNBX, WOEN)
CNBX PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023
CNBX PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K)
CNBX Pharmaceuticals Inc. Announces Board Resignations
CNBX PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022
CNBX PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K)
Shaul Yemal Resigns Position as Director and Board Member Cnbx Pharmaceuticals Inc
CNBX PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2022
CNBX Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt
CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma
CNBX Pharmaceuticals Inc. acquired unknown stake in TaGeza Biopharmaceuticals Ltd.
CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DK5G Aktie
  4. A116WM Aktie
  5. Nachrichten Cannabics Pharmaceuticals Inc.
  6. Andere Sprachen